NeoGenomics Inc (NEO)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 42.87% | 42.47% | 41.54% | 41.24% | 41.34% | 40.68% | 39.96% | 38.60% | 36.86% | 35.50% | 35.70% | 37.80% | 38.62% | 41.12% | 42.17% | 39.89% | 41.83% | 41.94% | 43.29% | 46.77% |
| Operating profit margin | -13.35% | -13.71% | -14.54% | -16.51% | -17.42% | -19.02% | -22.60% | -25.38% | -30.62% | -34.79% | -35.36% | -32.03% | -24.52% | -14.79% | -5.58% | -5.24% | -3.15% | -4.05% | -4.50% | 1.23% |
| Pretax margin | -12.09% | -12.39% | -13.28% | -14.91% | -16.41% | -18.67% | -22.75% | -26.41% | -31.26% | -35.84% | -33.02% | -9.69% | -3.11% | 7.57% | 12.70% | -6.46% | -3.16% | -4.51% | -4.43% | 0.53% |
| Net profit margin | -11.92% | -12.07% | -12.50% | -13.79% | -14.87% | -16.76% | -20.79% | -23.71% | -28.30% | -32.88% | -30.00% | -7.33% | -1.72% | 10.08% | 14.68% | -2.42% | 0.94% | -1.16% | -1.33% | 0.82% |
NeoGenomics Inc's profitability ratios have shown mixed performance over the past few years.
- The gross profit margin, which indicates the percentage of revenue that exceeds the cost of goods sold, has fluctuated within a range of 35.70% to 42.87% during the period. The company has generally maintained a healthy gross profit margin above 35%, reflecting its ability to generate profits from its core operations.
- On the other hand, the operating profit margin has been negative throughout most of the period, indicating that the company's operating expenses have outstripped its operating income. Despite some improvements, the operating profit margin remains below zero, with the lowest point recorded at -35.36%.
- The pretax margin, which shows the percentage of each dollar of revenue that represents pre-tax profit, has also been negative, with fluctuations ranging from -35.84% to 12.70%. The company experienced significant variability in its pretax margin, with some periods showing positive performance while others remained in negative territory.
- The net profit margin, which reflects the company's bottom line profitability after all expenses have been deducted, has also been negative during the period. The net profit margin fluctuated between -32.88% and 14.68%, highlighting the significant volatility in the company's overall profitability.
Overall, NeoGenomics Inc faces challenges in achieving positive profitability ratios consistently, as evidenced by the negative margins across different periods. The company may need to focus on cost management, revenue growth, and operational efficiency to enhance its profitability in the future.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -5.38% | -5.38% | -5.56% | -6.15% | -6.13% | -6.51% | -7.35% | -7.87% | -8.97% | -9.84% | -9.65% | -8.51% | -6.35% | -3.76% | -1.44% | -1.59% | -1.42% | -1.79% | -1.93% | 0.71% |
| Return on assets (ROA) | -4.81% | -4.74% | -4.78% | -5.14% | -5.23% | -5.74% | -6.76% | -7.35% | -8.29% | -9.30% | -8.19% | -1.95% | -0.45% | 2.56% | 3.78% | -0.73% | 0.42% | -0.52% | -0.57% | 0.47% |
| Return on total capital | -8.21% | -8.06% | -8.40% | -9.02% | -9.31% | -10.44% | -12.39% | -13.80% | -15.64% | -18.82% | -16.57% | -5.48% | -2.42% | 3.72% | 5.99% | -2.02% | -0.31% | -1.36% | -1.54% | 1.17% |
| Return on equity (ROE) | -8.72% | -8.56% | -8.58% | -9.12% | -9.34% | -10.17% | -11.99% | -12.89% | -14.45% | -16.12% | -14.07% | -3.32% | -0.75% | 4.29% | 6.25% | -1.30% | 0.60% | -0.74% | -0.82% | 0.68% |
NeoGenomics Inc's profitability ratios have shown a declining trend over the past few years. The Operating return on assets (Operating ROA) has consistently been negative, ranging from -8.51% to -5.38% as of December 31, 2024. This indicates that the company's operating income generated from its assets has been insufficient to cover its operating expenses.
Similarly, the Return on assets (ROA) has also been negative, ranging from -9.30% to -4.74% as of September 30, 2024, reflecting the company's struggle to generate profits from its total assets.
The Return on total capital has also been negative, ranging from -18.82% to -8.06% as of September 30, 2024, indicating that the company's return on the invested capital, including debt and equity, has been insufficient.
Finally, the Return on equity (ROE) has shown a negative trend, ranging from -16.12% to -8.72% as of December 31, 2024, illustrating the company's inability to generate significant returns for its shareholders.
Overall, NeoGenomics Inc's profitability ratios suggest a concerning performance in terms of generating returns for both its assets and capital, highlighting the need for strategic improvements to enhance profitability and shareholder value.